Mazdutide

In today's world, Mazdutide has captured the attention of millions of people around the world. Whether due to its impact on society, its historical relevance or its influence on popular culture, Mazdutide has become a constant topic of conversation today. As we explore the various aspects and facets that make up Mazdutide, it becomes evident that its importance and scope are significant on multiple levels. In this article, we will examine in detail the various aspects of Mazdutide and how it has left an indelible mark on contemporary society.

Mazdutide
Clinical data
Other namesIBI362; LY3305677
Legal status
Legal status
  • Investigational
Identifiers
  • 20-amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6--3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC207H317N45O65
Molar mass4476.063 g·mol−1
3D model (JSmol)
  • C((C(=O)N(CC1=CC=CC=C1)C(=O)N((C)O)C(=O)N(CO)C(=O)N(CC(=O)O)C(=O)N(CC2=CC=C(C=C2)O)C(=O)N(CO)C(=O)N(CCCCN)C(=O)N(CC3=CC=C(C=C3)O)C(=O)N(CC(C)C)C(=O)N(CC(=O)O)C(=O)N(CCC(=O)O)C(=O)N(CCCCN)C(=O)N(CCCCN)C(=O)N(C)C(=O)N(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N(CCC(=O)O)C(=O)N(CC4=CC=CC=C4)C(=O)N(C(C)C)C(=O)N(CCC(=O)O)C(=O)N(CC5=CNC6=CC=CC=C65)C(=O)N(CC(C)C)C(=O)N(CC(C)C)C(=O)N(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N7CCC7C(=O)N(CO)C(=O)NCC(=O)N)NC(=O)CNC(=O)(CCC(=O)N)NC(=O)C(C)(C)NC(=O)(CC8=CNC=N8)N)O
  • InChI=1S/C207H317N45O65/c1-116(2)93-144(189(295)230-138(70-76-168(271)272)179(285)221-107-162(264)219-109-166(268)252-86-46-57-157(252)201(307)245-154(110-253)181(287)220-106-159(213)261)234-190(296)145(94-117(3)4)236-194(300)151(100-127-104-218-133-52-37-36-51-131(127)133)240-188(294)142(73-79-171(277)278)233-202(308)174(119(7)8)249-197(303)149(96-123-47-30-28-31-48-123)238-187(293)141(72-78-170(275)276)231-183(289)135(56-41-45-83-215-164(266)113-316-91-90-315-88-85-217-165(267)114-317-92-89-314-87-84-216-160(262)75-69-143(205(311)312)225-161(263)58-34-26-24-22-20-18-16-14-15-17-19-21-23-25-27-35-59-167(269)270)226-177(283)120(9)224-182(288)134(53-38-42-80-208)227-184(290)136(54-39-43-81-209)228-186(292)140(71-77-169(273)274)232-195(301)152(102-172(279)280)241-191(297)146(95-118(5)6)235-192(298)147(98-125-60-64-129(258)65-61-125)237-185(291)137(55-40-44-82-210)229-199(305)155(111-254)244-193(299)148(99-126-62-66-130(259)67-63-126)239-196(302)153(103-173(281)282)242-200(306)156(112-255)246-204(310)176(122(11)257)250-198(304)150(97-124-49-32-29-33-50-124)243-203(309)175(121(10)256)248-163(265)108-222-180(286)139(68-74-158(212)260)247-206(313)207(12,13)251-178(284)132(211)101-128-105-214-115-223-128/h28-33,36-37,47-52,60-67,104-105,115-122,132,134-157,174-176,218,253-259H,14-27,34-35,38-46,53-59,68-103,106-114,208-211H2,1-13H3,(H2,212,260)(H2,213,261)(H,214,223)(H,215,266)(H,216,262)(H,217,267)(H,219,264)(H,220,287)(H,221,285)(H,222,286)(H,224,288)(H,225,263)(H,226,283)(H,227,290)(H,228,292)(H,229,305)(H,230,295)(H,231,289)(H,232,301)(H,233,308)(H,234,296)(H,235,298)(H,236,300)(H,237,291)(H,238,293)(H,239,302)(H,240,294)(H,241,297)(H,242,306)(H,243,309)(H,244,299)(H,245,307)(H,246,310)(H,247,313)(H,248,265)(H,249,303)(H,250,304)(H,251,284)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,311,312)/t120-,121+,122+,132-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,174-,175-,176-/m0/s1
  • Key:XRBYWQZGSZWYEJ-HMQIFOERSA-N

Mazdutide (also known as IBI362 or LY3305677) is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).[1][2][3] The drug is developed by Eli Lilly and is currently in multiple Phase III studies.[4][5]

References

  1. ^ Jiang, Hongwei; Pang, Shuguang; Zhang, Yawei; Yu, Ting; Liu, Meng; Deng, Huan; Li, Li; Feng, Liqi; Song, Baili; Han-Zhang, Han; Ma, Qingyang; Qian, Lei; Yang, Wenying (24 June 2022). "A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes". Nature Communications. 13 (1): 3613. Bibcode:2022NatCo..13.3613J. doi:10.1038/s41467-022-31328-x. ISSN 2041-1723. PMC 9232612. PMID 35750681.
  2. ^ Ji, Linong; Gao, Leili; Jiang, Hongwei; Yang, Jing; Yu, Lei; Wen, Jie; Cai, Chenghang; Deng, Huan; Feng, Liqi; Song, Baili; Ma, Qingyang; Qian, Lei (December 2022). "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial". eClinicalMedicine. 54: 101691. doi:10.1016/j.eclinm.2022.101691. PMC 9561728. PMID 36247927.
  3. ^ Ji, Linong; Jiang, Hongwei; An, Pei; Deng, Huan; Liu, Meng; Li, Li; Feng, Liqi; Song, Baili; Han-Zhang, Han; Ma, Qingyang; Qian, Lei (September 2021). "IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study". eClinicalMedicine. 39: 101088. doi:10.1016/j.eclinm.2021.101088. PMC 8374649. PMID 34430840.
  4. ^ Deswal, Phalguni (2024-09-12). "EASD 2024: Innovent shows off mazdutide's efficacy in diabetes and obesity". Clinical Trials Arena. Retrieved 2024-11-10.
  5. ^ "Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?". Retrieved 4 November 2023.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.